2001
DOI: 10.1016/s0165-5728(01)00261-2
|View full text |Cite
|
Sign up to set email alerts
|

Serum and CSF levels of MCP-1 and IP-10 in multiple sclerosis patients with acute and stable disease and undergoing immunomodulatory therapies

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

19
97
4
2

Year Published

2001
2001
2012
2012

Publication Types

Select...
9
1

Relationship

0
10

Authors

Journals

citations
Cited by 158 publications
(122 citation statements)
references
References 21 publications
19
97
4
2
Order By: Relevance
“…Recently accumulated evidence has demonstrated an elevated serum IP-10 level in various diseases, including inflammatory disease, and has shown its utility as a clinically useful biomarker. [13][14][15] For instance, Tang et al 16 demonstrated that IP-10 is an independent predictor of outcome for severe acute respiratory syndrome patients. Another group has demonstrated elevated IP-10 levels in patients with coronary artery disease.…”
Section: Discussionmentioning
confidence: 99%
“…Recently accumulated evidence has demonstrated an elevated serum IP-10 level in various diseases, including inflammatory disease, and has shown its utility as a clinically useful biomarker. [13][14][15] For instance, Tang et al 16 demonstrated that IP-10 is an independent predictor of outcome for severe acute respiratory syndrome patients. Another group has demonstrated elevated IP-10 levels in patients with coronary artery disease.…”
Section: Discussionmentioning
confidence: 99%
“…These data indicate that MCP-1 is one of the major proinflammatory cytokines. In the central nervous system, MCP-1 was detected in the serum and CSF of patients with multiple sclerosis and the ischemic stroke (Franciotta et al, 2001;Losy and Zaremba, 2001). Previous studies have reported that MCP-1 deficiency in genetically altered mice and the nonpeptide C-C chemokine receptor antagonist TAK-779 reduced infarct volume and macrophage accumulations in the stroke model (Hughes et al, 2001;Takami et al, 2002), and that anti-MCP-1-neutralizing antibody attenuated N-methyl-D-aspartate-induced brain injury in the striatum and hippocampus (Galasso et al, 2000).…”
Section: Discussionmentioning
confidence: 99%
“…The CXC chemokine ligand 10 (CXCL10) is thought to play an important role in neuroinflammatory diseases and its action may involve neuronal cells (van Marle et al, 2004). During CNS neuroinflammation expression of CXCL10 is elevated several fold (Franciotta et al, 2001;Kieseier et al, 2002;Kolb et al, 1999;Letendre et al, 1999;Sorensen et al, 1999;Xia et al, 2000) and occurs in a variety of CNS cells including astrocytes, microglia, and neurons (Asensio and Campbell, 1999;Carter et al, 2007;Kutsch et al, 2000;Ransohoff et al, 1993;Rossi and Zlotnik, 2000;Shen et al, 2006;Simpson et al, 2000;Wang et al, 1998).…”
Section: Introductionmentioning
confidence: 99%